The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease. Familial hypercholesterolaemia (FH), diagnosed based on the clinical features seen in patients with a posi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2016-01-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4439 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329849712246784 |
|---|---|
| author | Natalie Schellack Gustav Schellack E. Bronkhorst |
| author_facet | Natalie Schellack Gustav Schellack E. Bronkhorst |
| author_sort | Natalie Schellack |
| collection | DOAJ |
| description | Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease. Familial hypercholesterolaemia (FH), diagnosed based on the clinical features seen in patients with a positive family history, constitutes a heritable disorder involving a single gene. FH can exist in either the heterozygous or homozygous form, and may be differentiated based on clinical features and genetic studies. A novel drug target, proprotein convertase subtilisin/kexin type 9 (PCSK9), has resulted in the development and subsequent approval of new, targeted monoclonal antibodies in the treatment of FH. Targeting PCSK9 with monoclonal antibodies, i.e. evolocumab and alirocumab, inhibits the degradation of LDL receptors, and against a background of optimised statin therapy, increases the life expectancy of patients with hypercholesterolaemia by reducing the incidence and severity of coronary artery disease. |
| format | Article |
| id | doaj-art-5658059bdbac431eb0e3748d1686b2e3 |
| institution | Kabale University |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-5658059bdbac431eb0e3748d1686b2e32025-08-20T03:47:08ZengAOSISSouth African Family Practice2078-61902078-62042016-01-0158110.4102/safp.v58i1.44393585The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular riskNatalie Schellack0Gustav Schellack1E. Bronkhorst2Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences UniversityPrivate Sector, Pharmaceutical IndustryDepartment of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences UniversityHypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease. Familial hypercholesterolaemia (FH), diagnosed based on the clinical features seen in patients with a positive family history, constitutes a heritable disorder involving a single gene. FH can exist in either the heterozygous or homozygous form, and may be differentiated based on clinical features and genetic studies. A novel drug target, proprotein convertase subtilisin/kexin type 9 (PCSK9), has resulted in the development and subsequent approval of new, targeted monoclonal antibodies in the treatment of FH. Targeting PCSK9 with monoclonal antibodies, i.e. evolocumab and alirocumab, inhibits the degradation of LDL receptors, and against a background of optimised statin therapy, increases the life expectancy of patients with hypercholesterolaemia by reducing the incidence and severity of coronary artery disease.https://safpj.co.za/index.php/safpj/article/view/4439alirocumabevolocumabcardiovascular risk factorsfamilial hypercholesterolaemiapcsk9proprotein convertase subtilisin/kexin type 9ldl cholesterolldl receptor |
| spellingShingle | Natalie Schellack Gustav Schellack E. Bronkhorst The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk South African Family Practice alirocumab evolocumab cardiovascular risk factors familial hypercholesterolaemia pcsk9 proprotein convertase subtilisin/kexin type 9 ldl cholesterol ldl receptor |
| title | The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk |
| title_full | The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk |
| title_fullStr | The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk |
| title_full_unstemmed | The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk |
| title_short | The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk |
| title_sort | role of proprotein convertase subtilisin kexin type 9 inhibitors in managing cardiovascular risk |
| topic | alirocumab evolocumab cardiovascular risk factors familial hypercholesterolaemia pcsk9 proprotein convertase subtilisin/kexin type 9 ldl cholesterol ldl receptor |
| url | https://safpj.co.za/index.php/safpj/article/view/4439 |
| work_keys_str_mv | AT natalieschellack theroleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk AT gustavschellack theroleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk AT ebronkhorst theroleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk AT natalieschellack roleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk AT gustavschellack roleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk AT ebronkhorst roleofproproteinconvertasesubtilisinkexintype9inhibitorsinmanagingcardiovascularrisk |